NCT04060849

Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Fred Hutchinson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic, alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and may also prevent community acquired respiratory virus infection in stem cell transplant recipients.

Detailed description

OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose two times daily (BID) up to 100 days after transplant. ARM II: Patients receive standard of care. After completion of study, patients are followed up every week for 6 weeks and then every alternate week until day 100.

Conditions

• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Solid Neoplasm

Interventions

Type	Name	Description
DRUG	Nozin	Given via nasal single-use popswabs or single-use cotton tipped applicators
OTHER	Best Practice	Receive standard of care

Timeline

• Start date: 2019-09-03
• Primary completion: 2020-04-12
• Completion: 2020-04-12
• First posted: 2019-08-19
• Last updated: 2024-11-08

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study